 |
|
|
| |
A POOLED ANALYSIS OF TWO RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIALS (STARTVerso1 AND 2) OF FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTIONBACKGROUND
|
| |
| |
Download the PDF here
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
DM Jensen1, T Asselah2, D Dieterich3, GR Foster4, MS Sulkowski5, S Zeuzem6, P Mantry7, C Moreno8, D Ouzan9, M Wright10, LE Morano11, R Buynak12, M Bourlière13, T Hassanein14, S Nishiguchi15, J-H Kao16, M Omata17, SW Paik18, DK Wong19, E Tam20, K Kaita21, SV Feinman22, JO Stern23, M Garcia23, AM Quinson23, F Voss24, J-P Gallivan24, WO Böcher24, P Ferenci25, on behalf of the STARTVerso1 and STARTVerso2 Study Groups
1University of Chicago Medicine, Chicago, IL, USA; 2Hôpital Beaujon, APHP, University Paris-Diderot and INSERM CRB3, Clichy, France; 3Mount Sinai School of Medicine, New York, NY, USA; 4Queen Mary, University of London, London, UK; 5Johns Hopkins University School of Medicine, Baltimore, MD, USA; 6J.W.Goethe University Hospital, Frankfurt, Germany; 7The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, USA; 8Hôpital Universitaire Erasme, Universite Libre de Bruxelles, Brussels, Belgium; 9Institut Arnault Tzanck, St Laurent du Var, France; 10Wellcome Trust Clinical Research Facility, Southampton, UK; 11Hospital Meixoeiro, Vigo, Spain; 12Northwest Indiana Center for Clinical Research, Valparaiso, IN, USA 13Hopital Saint Joseph, Marseille, France; 14Southern California Liver Centers, Coronado, CA, USA; 15Hyogo College of Medicine, Hyogo, Japan; 16National Taiwan University Hospital, Taipei, Taiwan; 17Yamanishi Central and Kita Hospitals, Yamanishi, Japan; 18Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea; 19Toronto Western Hospital Liver Center, Toronto, ON, Canada; 20LAIR Centre, Vancouver, BC, Canada; 21HSC University of Manitoba, Winnipeg, MB, Canada; 22Hepatitis Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; 23Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 24Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; 25Medical University of Vienna, Vienna, Austria
|
| |
|
|
|
|
|
